MedTrace Logo

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2018-11-15

Study results available
· View outcomes & findings →

Summary

To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG

LY2127399

Administered via Injection

DRUG

Placebo

Administered via Injection

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-02-28
Completion
2012-06-30

Countries

  • United States
  • Bulgaria
  • Czechia
  • France
  • Germany
  • Hungary
  • Israel
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00882999 on ClinicalTrials.gov